AbCellera reported a decrease in total revenue to $5.5 million compared to $9.4 million in Q3 2020, which is attributable to the reduction of milestone payments associated with COVID-19 treatments. The company added 17 programs under contract and two new partners, resulting in a cumulative total of 155 programs under contract with 35 different partners. One new molecule advanced into the clinic, bringing the cumulative total to five. The net loss was $21.4 million, or ($0.08) per share.